Business Wire

CLEO

20.5.2019 09:02:06 CEST | Business Wire | Press release

Share
Cleo to Showcase End-to-End Approach to Ecosystem Integration at Gartner AADI in London

Gartner’s Application Architecture, Development & Integration (AADI) Summit returns to London to provide strategies for solving the pervasive challenges of orchestrating workflows between external B2B and application ecosystems with internal business systems. Cleo , the global leader in ecosystem integration solutions, will be exhibiting in Booth S3 to demonstrate how successful organisations leverage its “outside-in” approach to create seamless end-to-end workflows and help optimize business processes.

The Gartner AADI 2019 event , taking place 20-21 May at Park Plaza Westminster, is designed to empower IT and business professionals in transforming their application architecture, agile development, and integration strategies. The event’s focus on application strategies and data processes in the era of the cloud highlights the need for better ways to execute application integration, an inescapable challenge in today’s business landscape.

According to the 2019 State of Ecosystem and Integration Application Report , integration is a constant battle for organisations, with 25% of companies struggling to integrate new applications with legacy systems. All told, unreliable partner and application integrations are costing companies approximately $500,000 every year. Cleo will showcase at the Gartner AADI summit how to solve these challenges using an innovative approach that integrates the dynamic ecosystem of people, partners, customers, systems, applications, and things and supports the critical data flows driving revenue.

About Cleo Integration Cloud

Today’s data exchange requirements often are dictated by the partners, suppliers, customers, vendors, and all their respective technologies comprising a modern business ecosystem, and it demands a change in how we view traditional integration patterns. Conference-goers visiting the Cleo booth will learn hands-on about the business benefits of technology embracing this fresh POV – integration that prioritises external customer and trading partner data processes and integrates them seamlessly into internal workflows – via the Cleo Integration Cloud platform.

Cleo’s flagship offering is a single, hybrid integration platform enabling organisations to connect, transform, integrate, orchestrate, and analyse end-to-end application, B2B, cloud, and data integrations for improved visibility across global business ecosystems. Cleo Integration Cloud facilitates the heavy lifting of integration while also providing dynamic dashboards to empower technical and business users to make better decisions, create stronger relationships with trading partners, and accelerate growth as data requirements evolve. The result is end-to-end transparency throughout internal networks and external business ecosystems, which enables organisations to maximise the value of their application investments.

Agenda Highlights

The opening keynote for this year’s Gartner AADI summit is titled, “Optimize, Integrate and Transform to Achieve Your Digital Future” and features Gartner’s Elizabeth Golluscio, managing vice president, Keith Guttridge, senior director analyst, and Mark O'Neill, VP analyst. The speakers will explore how organisations pursuing digital transformation must apply modern digital application and integration strategies to advance those initiatives.

The agenda also features a number of topics spanning cloud integration challenges, strategic application trends, modernising core systems, postmodern ERP integration, and how smart application integration delivers next-generation customer experiences. The nature of the 2019 agenda further emphasizes the value an ecosystem-driven approach can have in designing application integration processes that support innovation, align with business goals, and deliver competitive advantage.

“Organisations are at a tipping point in how they integrate all the ERPs, CRMs, e-commerce, and other business-critical applications they deploy almost daily,” said Cleo CMO Tushar Patel . “It’s individual departments and lines of business that are driving technology investment, rather than the traditional IT teams, and it requires a change in how they approach application integration. Today’s integration technology should give companies a path to optimising their core business processes while solving external B2B and internal application integration challenges simultaneously.”

Patel adds: “The companies treating application and B2B interactions as separate, disparate business processes are leaving value on the table and will get left behind.”

Come see Cleo at Booth S3 for a Cleo-themed cocktail – an “Ecosystem Integration Elixir” – and to learn how Cleo customers are achieving success every day with Cleo Integration Cloud. To learn more about Cleo, and how Cleo Integration Cloud can help your business, visit our website – www.cleo.com .

For more insights on what to expect at the event, read the blog titled, “Ecosystem Integration & Value Beyond the Gartner AADI London Agenda.”

About Gartner AADI 2019

The Gartner Application Architecture, Development & Integration Summit 2019 is designed for application leaders to learn about crafting leading-edge applications, architectures and strategies leveraging microservices, DevOps and artificial intelligence, and more. Attendees can gain intensive learning and actionable insight as they plan to drive growth through digital business transformation.

About Cleo

Cleo is an ecosystem integration software company focused on business outcomes, ensuring each customer’s potential is realized by delivering solutions that make it easy to discover and create value through the movement and integration of enterprise data. Cleo gives customers a strategic, “outside-in” visibility into the critical end-to-end business flows happening across their ecosystems of partners and customers, marketplaces, and internal cloud and on-premise applications. Our solutions empower teams to drive business agility, accelerate onboarding, facilitate modernisation of key business processes, and capture new revenue streams by reimagining and remastering their digital ecosystem through robust application, B2B, and data integration technologies. For more information, visit www.cleo.com or call +1.815.282.7695.

Contact:

Media Contacts Matt Torman Senior Manager, Marketing Communications Cleo +1.815.282.7610

Drew Smith Senior Account Manager 10Fold Communications (for Cleo) +1.415.800.5374

Link:

ClickThru

Social Media:

https://www.facebook.com/CleoCommunications

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye